News
Checkpoint inhibitor rechallenge is possible for select patients
Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths...
News
FDA approves abemaciclib plus aromatase inhibitor as initial therapy
Abemaciclib plus an aromatase inhibitor was approved as initial endocrine-based therapy in women with HR-positive, HER2-negative metastatic breast...
News
Only half of appropriate COPD patients get long-acting bronchodilators
The findings beg the issue of why clinicians overrely on short-acting rather than recommended long-acting bronchodilators for maintenance...
News
Lomitapide manufacturer will plead guilty to two misdemeanor charges of misbranding
Lomitapide's rare disorder target was portrayed as vague to extend its use to more patients, according to the FDA.
News
Polycythemia vera test detects JAK2 V617F/G1849T mutation
The ipsogen JAK2 RGQ PCR Kit has been given marketing authorization by the Food and Drug Administration.
Article
VIDEO: CPX-351 may allow more high-risk AML patients to have allogeneic transplants
SAN DIEGO – Induction therapy with the investigational drug CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed more...
Article
Factor VIII microcapsules eyed for eluding neutralizing antibodies
Using platelet microcapsules to deliver factor VIII, a process that is expected to increase factor VIII efficacy and avoid the development of...
Article
Investigational AML drugs boosted remission rates
CPX-351 (Vyxeos), a liposomal formulation of cytarabine and daunorubicin, allowed a higher proportion of patients over age 60 with secondary AML...
Article
Oxygen therapy no advantage in stable COPD with moderate desaturation
Long-term supplemental oxygen had no benefit on multiple outcome measures in patients with stable COPD and resting or exercise-induced moderate...
Article
Age of blood did not affect mortality in transfused patients
In-hospital mortality did not vary for patients who received transfusions of blood that had been stored for 2 weeks and for patients who got blood...
Article
Minimal residual disease status predicts 10-year survival in CLL
Patients who have chronic lymphocytic leukemia and achieve minimal residual disease negativity have a high probability of long-term progression-...
Article
CD49d trumps novel recurrent mutations for predicting overall survival in CLL
CD49d was a strong predictor of overall survival in a cohort of 778 unselected patients with chronic lymphocytic leukemia.
News
VTE risk appears to vary over time in patients with multiple myeloma
Key clinical point: Patients with multiple myeloma should be assessed for VTE risk and thromboprophylaxis on an ongoing basis throughout the...
News
Quality of life measures comparable for panobinostat or placebo in combination with bortezomib and dexamethasone
Key clinical point: Quality of-life measures were comparable for multiple myeloma patients whether they received panobinostat or placebo in...